ENDPOINTS

Sorriso Pharmaceuticals outlines Phase 1b ulcerative colitis data for oral antibody

Private startup Sorriso Pharmaceuticals laid out Phase 1b data at a medical conference last weekend as part of its effort to bring an oral antibody to market for IBD patients. The results come after Sorriso ...

Feb 27, 2025 - 11:12
 0
Sorriso Pharmaceuticals outlines Phase 1b ulcerative colitis data for oral antibody
Private startup Sorriso Pharmaceuticals laid out Phase 1b data at a medical conference last weekend as part of its effort to bring an oral antibody to market for IBD patients. The results come after Sorriso ...
Read More

Tags:

Previous Article

A rare 'parade' of all 7 planets will move across the night sky this week

Next Article

'Galloping' bubbles could act as tiny robotic vacuum cleaners

Related Posts

UPDATED: Moderna earnings: Losses narrow as biotech cuts costs

UPDATED: Moderna earnings: Losses narrow as biotech cut...

Feb 14, 2025  0

Major FDA staff cuts would slow drug reviews, experts say

Major FDA staff cuts would slow drug reviews, experts say

Feb 9, 2025  0

Hunger-suppressing biotech Aardvark raises $94M in IPO

Hunger-suppressing biotech Aardvark raises $94M in IPO

Feb 13, 2025  0